Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | CA2 | P00918 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131062 | 1.00 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2855689 | 1.00 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL131061 | 0.98 | MEN1 (0.60) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL21271788 | 0.98 | MEN1 (0.60) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL138402 | 0.95 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL2247530 | 0.95 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL8171267 | 0.95 | MEN1 (0.56) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL138401 | 0.94 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL7352392 | 0.94 | MEN1 (0.55) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL12215023 | 0.94 | TDP1 (0.58) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528834-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250312514-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | ALLERGAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250114466-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2025-04-10 | — | — | US | disclosed |
| EP-4457229-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | Byondis B.V. (NL) | 2024-11-06 | — | — | EP | disclosed |
| US-20240316246-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | ALLERGAN INC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230277725-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | ALLERGAN INC (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023126297-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126297-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-102443048-A | Synthetic method of 5-membered cyclopeptide | JIANGSU YEW PHARMACEUTICAL CO LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-2119718-B1 | MACROCYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| EP-2119718-A1 | MACROCYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1209147-A1 | CARBOXYLIC ACID DERIVATIVES AND ADHESION MOLECULE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056510-A1 | Macrocyclic Compound | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 2984/4885KMT2A 3546/4885GAA 362/4885 |
| US-20250114466-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | MEN1 1545/4885KMT2A 1224/4885GAA 2610/4885 |
| US-20240316246-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | CD44, CHIT1, CHIA | MEN1 3259/4885KMT2A 4110/4885GAA 357/4885 |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | MEN1 2114/4885KMT2A 2978/4885GAA 4404/4885 |
| US-12528834-B2 | Method for producing peptide compound | VIP, IAPP, NPPA | MEN1 355/4885KMT2A 3946/4885GAA 2200/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | MEN1 1545/4885KMT2A 1224/4885GAA 2610/4885 |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MEN1 2302/4885KMT2A 3407/4885GAA 283/4885 |
| US-20250312514-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | CD44, CHIT1, CHIA | MEN1 3259/4885KMT2A 4110/4885GAA 357/4885 |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | MEN1 488/4885KMT2A 2996/4885GAA 3279/4885 |
| US-20230277725-A1 | COACERVATE HYALURONAN HYDROGELS FOR DERMAL FILLER APPLICATIONS | CD44, CHIT1, CHIA | MEN1 3259/4885KMT2A 4110/4885GAA 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.